Top-Rated StocksTop-RatedNASDAQ:ZVRA Zevra Therapeutics (ZVRA) Stock Price, News & Analysis $9.30 -0.06 (-0.64%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$9.51 +0.21 (+2.20%) As of 06:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Zevra Therapeutics Stock (NASDAQ:ZVRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zevra Therapeutics alerts:Sign Up Key Stats Today's Range$9.23▼$9.4750-Day Range$8.81▼$12.7952-Week Range$6.19▼$13.16Volume922,312 shsAverage Volume1.63 million shsMarket Capitalization$522.06 millionP/E RatioN/ADividend YieldN/APrice Target$23.71Consensus RatingBuy Company Overview Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. Read More Zevra Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreZVRA MarketRank™: Zevra Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 333rd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingZevra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageZevra Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Zevra Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Zevra Therapeutics are expected to grow in the coming year, from ($1.95) to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zevra Therapeutics is -44.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zevra Therapeutics is -44.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZevra Therapeutics has a P/B Ratio of 4.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zevra Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.59% of the float of Zevra Therapeutics has been sold short.Short Interest Ratio / Days to CoverZevra Therapeutics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Zevra Therapeutics has recently decreased by 5.31%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZevra Therapeutics does not currently pay a dividend.Dividend GrowthZevra Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.59% of the float of Zevra Therapeutics has been sold short.Short Interest Ratio / Days to CoverZevra Therapeutics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Zevra Therapeutics has recently decreased by 5.31%, indicating that investor sentiment is improving significantly. News and Social Media2.1 / 5News Sentiment0.80 News SentimentZevra Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Zevra Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 16 people have searched for ZVRA on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Zevra Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $45,800.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Zevra Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 35.03% of the stock of Zevra Therapeutics is held by institutions.Read more about Zevra Therapeutics' insider trading history. Receive ZVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZVRA Stock News HeadlinesZevra Therapeutics (NASDAQ:ZVRA) Director John Bode Buys 5,000 SharesAugust 21, 2025 | insidertrades.comZevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)August 28 at 7:30 AM | globenewswire.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI. | Brownstone Research (Ad)Zevra Therapeutics to Participate at Upcoming Investor Conferences in SeptemberAugust 26 at 7:30 AM | globenewswire.comZevra Therapeutics (NASDAQ:ZVRA) Sees Strong Trading Volume Following Insider Buying ActivityAugust 22, 2025 | americanbankingnews.comZevra Therapeutics rumor highlighted in Betaville blogAugust 21, 2025 | msn.comZevra Therapeutics gains amid takeover speculationAugust 21, 2025 | msn.comTourmaline Bio (NASDAQ:TRML) versus Zevra Therapeutics (NASDAQ:ZVRA) Head to Head ReviewAugust 20, 2025 | americanbankingnews.comSee More Headlines ZVRA Stock Analysis - Frequently Asked Questions How have ZVRA shares performed this year? Zevra Therapeutics' stock was trading at $8.34 at the start of the year. Since then, ZVRA stock has increased by 11.5% and is now trading at $9.30. How were Zevra Therapeutics' earnings last quarter? Zevra Therapeutics, Inc. (NASDAQ:ZVRA) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.15. The company had revenue of $20.40 million for the quarter, compared to analysts' expectations of $16.96 million. Zevra Therapeutics had a negative trailing twelve-month return on equity of 112.40% and a net margin of 4.33%. Read the conference call transcript. Who are Zevra Therapeutics' major shareholders? Zevra Therapeutics' top institutional shareholders include Adage Capital Partners GP L.L.C. (7.43%), Rubric Capital Management LP (3.49%), Geode Capital Management LLC (2.27%) and 683 Capital Management LLC (2.00%). Insiders that own company stock include Neil F Mcfarlane, R Laduane Clifton, John B Bode, Joshua Schafer, Thomas Anderson, Matthew R Plooster, Timothy J Sangiovanni, Corey Michael Watton and Tamara A Seymour. View institutional ownership trends. How do I buy shares of Zevra Therapeutics? Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zevra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Tesla (TSLA). Company Calendar Last Earnings5/13/2025Today8/28/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZVRA CIK1434647 Webwww.kempharm.com Phone(321) 939-3416Fax319-665-2577Employees20Year FoundedN/APrice Target and Rating Average Price Target for Zevra Therapeutics$23.71 High Price Target$29.00 Low Price Target$18.00 Potential Upside/Downside+155.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$105.51 million Net Margins4.33% Pretax Margin34.52% Return on Equity-112.40% Return on Assets-37.67% Debt Debt-to-Equity Ratio0.52 Current Ratio7.85 Quick Ratio7.81 Sales & Book Value Annual Sales$23.61 million Price / Sales22.11 Cash FlowN/A Price / Cash FlowN/A Book Value$2.09 per share Price / Book4.45Miscellaneous Outstanding Shares56,130,000Free Float54,788,000Market Cap$522.01 million OptionableOptionable Beta1.87 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ZVRA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.